Treace Medical's Stifel Appearance Highlights Medtech's MIS Battle

PONTE VEDRA, Fla. – November 03, 2026 — Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced today that its executive leadership will present at the Stifel 2026 Healthcare Conference on Wednesday, November 11. The fireside chat, scheduled for 1:20 pm ET, arrives at a highly consequential moment for the Florida-based medical technology company. As Treace attempts to defend its position as a pioneer in 3D bunion correction, it finds itself navigating a complex intersection of clinical triumphs, aggressive competitive shifts toward minimally invasive surgery (MIS), and persistent Wall Street skepticism regarding its path to profitability.

For years, Treace has anchored its market identity to the Lapiplasty 3D Bunion Correction System, a patented platform designed to address the root cause of bunions by securing the unstable joint in three dimensions. With an estimated 67 million Americans suffering from bunions—yielding approximately 1.1 million annual surgical candidates—the addressable market is vast. Yet, as the broader orthopedic sector pivots rapidly toward less invasive procedures, Treace's upcoming presentation at Stifel will serve as a critical forum to convince investors that its evolving portfolio can withstand the margin pressures of a changing surgical landscape.

The Economics of the Minimally Invasive Shift

The global bunion surgery market, valued at approximately $740.5 million in 2026, is projected to grow to $1.23 billion by 2034, representing a steady compound annual growth rate (CAGR) of 6.5%. However, the underlying currents of this growth reveal a structural transformation. While traditional open bunion surgery retains a 56.6% market share due to its established efficacy in complex deformities, the minimally invasive segment is accelerating at a much faster 9.4% CAGR.

This rapid adoption of MIS—which saw a 34% year-over-year increase in 2025-2026—is driven by patient demand for shorter recovery times, reduced postoperative pain, and better cosmetic outcomes. For Treace, this shift presents a double-edged sword. The company has historically dominated the comprehensive 3D correction space, but it now faces formidable competition from legacy orthopedic giants and agile startups alike. Stryker has aggressively pushed into the space with its PROstep MIS Lapidus and PRECISION MIS systems, while OSSIO recently launched its OSSIOfiber all-natural correction system.

"The transition toward less complex minimally invasive products has created a paradox where kit volumes increase, but average selling prices face downward pressure," noted one medtech industry analyst monitoring the orthopedic space. This dynamic has directly impacted Treace, forcing the company to adapt its commercial strategy to defend its market share against cheaper, simpler alternatives that appeal to surgeons looking for faster operating room turnover.

Clinical Moats vs. Financial Realities

Treace's strongest defense against commoditization lies in its clinical data. In September 2026, the company released the milestone 5-year results of its ALIGN3D study, demonstrating sustained, positive long-term outcomes for the Lapiplasty procedure. In an industry where long-term joint stability is the ultimate metric of success, this 5-year data provides a formidable clinical moat. Furthermore, the Centers for Medicare & Medicaid Services (CMS) increased the 2025 reimbursement rate for CPT code 28297, a vital code used for Lapiplasty procedures, offering a supportive macroeconomic tailwind.

However, Wall Street's focus has increasingly shifted from clinical validation to financial sustainability. Treace has experienced a turbulent 24 months marked by multiple guidance resets and concerns over its cash burn rate. The company is scheduled to release its highly anticipated third-quarter 2026 earnings on November 6, just days before the Stifel conference.

Consensus estimates project Q3 revenue of approximately $47.8 million, with an expected earnings per share (EPS) loss of $0.25 to $0.26. While Treace beat Q2 expectations with $45.38 million in revenue, the overarching narrative of a company "quickly burning through cash" continues to weigh on its valuation. Analysts forecast a total net loss of roughly $59.5 million for fiscal year 2026. The Stifel conference, therefore, represents a vital opportunity for management to articulate a clear timeline for operating leverage and cash flow break-even.

Strategic Expansion Beyond the Bunion

To counter the downward pressure on average selling prices and address the growing demand for MIS, Treace has systematically broadened its portfolio. The company is no longer solely reliant on the traditional Lapiplasty system. Its recent commercial efforts have heavily emphasized adjacent technologies, including the Adductoplasty Midfoot Correction System and the SpeedMTP 1st MTP Fusion System.

More importantly, Treace has directly answered the MIS threat with its own minimally invasive osteotomy solutions: the Nanoplasty 3D and Percuplasty Percutaneous systems. By integrating these systems with the IntelliGuide patient-specific pre-operative planning technology, Treace is attempting to create an ecosystem that locks surgeons into its proprietary digital and physical infrastructure.

"The strategy is clear: transition from being a single-procedure company to an indispensable foot and ankle platform," explained a healthcare strategist familiar with the company's product pipeline. "If they can bundle their advanced digital planning with both open and minimally invasive implants, they can protect their margins and increase the switching costs for surgeons."

Insider Confidence Amidst Institutional Skepticism

The tension between Treace's clinical achievements and its financial hurdles is starkly reflected in its stock performance. Trading under the ticker TMCI, the stock has been a battleground of volatility, swinging between a 52-week low of $1.17 and a high of $6.65.

Institutional sentiment remains cautious. The consensus rating among analysts is a "Hold," with Stifel itself reiterating that stance earlier this year alongside a $3.00 price target. Stifel's research notes have previously highlighted that while management is setting reasonable targets, the company remains in the early stages of a turnaround process. Short interest hovers around 3.97% of the public float, indicating that a contingent of the market expects further downside.

Yet, a deeper look at the capitalization table reveals a striking counter-narrative of internal conviction. Insider ownership is exceptionally high, with CEO John T. Treace holding nearly 45% of the company's shares. Over the past 90 days, insiders have purchased over $246,000 worth of stock on the open market. This aggressive insider buying suggests that leadership believes the market has fundamentally mispriced the company's long-term value and the protective power of its expanding patent portfolio.

When Treace's executives take the stage at the Stifel 2026 Healthcare Conference on November 11, the audience will be listening for more than just clinical updates. Investors will demand clarity on how the company plans to navigate the margin compression of the MIS revolution, stabilize its cash burn, and leverage its 5-year clinical data to regain pricing power in an increasingly crowded orthopedic market.